| 纯度 | >85% SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK2 |
| Uniprot No | P24941 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-298aa |
| 氨基酸序列 | MLGNSAPGPATREAGSALLALQQTALQEDQENINPEKAAPVQQPRTRAALAVLKSGNPRGLAQQQRPKTRRVAPLKDLPVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPRKPLVPLDYPMDGSFESPHTMDMSIILEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPESLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL&MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL |
| 预测分子量 | 35.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK2重组蛋白的3篇参考文献的简要信息：
1. **文献名称**：*Crystal structure of cyclin-dependent kinase 2*
**作者**：Jeffrey, P.D. et al.
**摘要**：该研究解析了CDK2与cyclin A复合物的晶体结构，揭示了CDK2的活性构象变化机制，实验通过重组表达人源CDK2蛋白，并验证其与cyclin的结合对激酶活性的调控作用。
2. **文献名称**：*Structural basis for inhibition of CDK2 by a selective small-molecule antagonist*
**作者**：Pavletich, N.P.
**摘要**：研究利用重组CDK2蛋白解析其与小分子抑制剂的复合物结构，阐明了抑制剂结合位点及构象选择性机制，为靶向CDK2的药物设计提供结构基础。
3. **文献名称**：*Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex*
**作者**：Schulman, B.A. et al.
**摘要**：通过重组表达CDK2和cyclin A蛋白，结合生化分析与结构生物学手段，揭示了CDK2被cyclin激活的具体分子机制，包括磷酸化位点和活性中心的重排过程。
(注：以上为示例性内容，实际文献名称及作者需根据具体论文调整。)
Cyclin-dependent kinase 2 (CDK2) is a serine/threonine kinase critical for regulating cell cycle progression, particularly during the G1-to-S phase transition. It functions by forming complexes with cyclin E or cyclin A, which activate its enzymatic activity to phosphorylate target substrates, such as retinoblastoma (Rb) protein, enabling DNA replication initiation. Dysregulation of CDK2 is implicated in uncontrolled cell proliferation, a hallmark of cancers, making it a therapeutic target for oncology research.
Recombinant CDK2 proteins are engineered using expression systems like *E. coli*, insect, or mammalian cells to produce highly purified, bioactive forms of the kinase. These proteins retain structural and functional integrity, including ATP-binding pockets, catalytic domains, and cyclin-binding regions, allowing researchers to study CDK2’s mechanisms, interactions, and inhibition in vitro. Tagging strategies (e.g., His-tags) facilitate purification and detection.
In drug discovery, recombinant CDK2 serves as a tool for high-throughput screening of inhibitors, such as CDK2/cyclin E interface blockers or ATP-competitive molecules. Structural studies using recombinant CDK2 have revealed conformational changes upon cyclin binding, guiding rational drug design. Mutant variants (e.g., kinase-dead or hyperactive forms) help dissect phosphorylation-dependent signaling pathways. Additionally, recombinant CDK2 aids in studying resistance mechanisms to pan-CDK inhibitors and developing isoform-specific therapies to minimize off-target effects.
Despite the emergence of newer CDKs (e.g., CDK4/6) as clinical targets, CDK2 remains relevant in cancers with cyclin E overexpression or CDK4/6 inhibitor resistance. Its recombinant form continues to bridge biochemical, structural, and translational research, offering insights into cell cycle control and anticancer strategies.
×
